熱門資訊> 正文

Belite Bio报告第二季度业绩

2026-08-13 22:44

Belite Bio press release (BLTE): Q2 non-GAAP net loss of $21.6M, compared to a non-GAAP net loss of $8.7M for the same period in 2025.
Cash and Cash Equivalents: As of June 30, 2026, the company had $279.9M in cash and cash equivalents, compared with $352.9M on December 31, 2025.

More on Belite Bio

Belite Bio: The Oral Route Is The Real Competitive Moat
Belite Bio, Inc (BLTE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Belite Bio, Inc (BLTE) Presents at 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026) - Slideshow
Belite Bio wins FDA priority review for lead candidate
These 10 mid-cap U.S. healthcare companies carry the market's most expensive valuations

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。